214 related articles for article (PubMed ID: 30706531)
21. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker.
Nobbio L; Visigalli D; Radice D; Fiorina E; Solari A; Lauria G; Reilly MM; Santoro L; Schenone A; Pareyson D;
Brain; 2014 Jun; 137(Pt 6):1614-20. PubMed ID: 24812204
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic Variability of Childhood Charcot-Marie-Tooth Disease.
Cornett KM; Menezes MP; Bray P; Halaki M; Shy RR; Yum SW; Estilow T; Moroni I; Foscan M; Pagliano E; Pareyson D; Laurá M; Bhandari T; Muntoni F; Reilly MM; Finkel RS; Sowden J; Eichinger KJ; Herrmann DN; Shy ME; Burns J;
JAMA Neurol; 2016 Jun; 73(6):645-51. PubMed ID: 27043305
[TBL] [Abstract][Full Text] [Related]
23. Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy.
Roa BB; Garcia CA; Lupski JR
Int J Neurol; 1991-1992; 25-26():97-107. PubMed ID: 11980069
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of Charcot-Marie-Tooth disease type 1A: gene dosage as a novel mechanism for a common autosomal dominant condition.
Roa BB; Lupski JR
Am J Med Sci; 1993 Sep; 306(3):177-84. PubMed ID: 8128981
[TBL] [Abstract][Full Text] [Related]
25. The 5' regulatory sequence of the PMP22 in the patients with Charcot-Marie-Tooth disease.
Sinkiewicz-Darol E; Kabzińska D; Moszyńska I; Kochański A
Acta Biochim Pol; 2010; 57(3):373-7. PubMed ID: 20842290
[TBL] [Abstract][Full Text] [Related]
26. Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development.
Lopez-Anido C; Poitelon Y; Gopinath C; Moran JJ; Ma KH; Law WD; Antonellis A; Feltri ML; Svaren J
Hum Mol Genet; 2016 Jul; 25(14):3055-3069. PubMed ID: 27288457
[TBL] [Abstract][Full Text] [Related]
27. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
[TBL] [Abstract][Full Text] [Related]
28. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.
Svaren J; Moran JJ; Wu X; Zuccarino R; Bacon C; Bai Y; Ramesh R; Gutmann L; Anderson DM; Pavelec D; Shy ME
Ann Neurol; 2019 Jun; 85(6):887-898. PubMed ID: 30945774
[TBL] [Abstract][Full Text] [Related]
29. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
30. A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot-Marie-Tooth neuropathy 1A.
Xu IRL; Danzi MC; Ruiz A; Raposo J; De Jesus YA; Reilly MM; Cortese A; Shy ME; Scherer SS; Herrmann DN; Fridman V; Baets J; Saporta M; Seyedsadjadi R; Stojkovic T; Claeys KG; Patel P; Feely S; Rebelo AP; ; Dohrn MF; Züchner S
J Peripher Nerv Syst; 2024 Apr; ():. PubMed ID: 38581130
[TBL] [Abstract][Full Text] [Related]
31. Genetic testing practices for Charcot-Marie-Tooth type 1A disease.
Tousignant R; Trepanier A; Shy ME; Siskind CE
Muscle Nerve; 2014 Apr; 49(4):478-82. PubMed ID: 23963961
[TBL] [Abstract][Full Text] [Related]
32. Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future.
Boutary S; Echaniz-Laguna A; Adams D; Loisel-Duwattez J; Schumacher M; Massaad C; Massaad-Massade L
Transl Res; 2021 Jan; 227():100-111. PubMed ID: 32693030
[TBL] [Abstract][Full Text] [Related]
33. Curcumin-cyclodextrin/cellulose nanocrystals improve the phenotype of Charcot-Marie-Tooth-1A transgenic rats through the reduction of oxidative stress.
Caillaud M; Msheik Z; Ndong-Ntoutoume GM; Vignaud L; Richard L; Favreau F; Faye PA; Sturtz F; Granet R; Vallat JM; Sol V; Desmoulière A; Billet F
Free Radic Biol Med; 2020 Dec; 161():246-262. PubMed ID: 32980538
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.
Rose KJ; Burns J; North KN
J Child Neurol; 2010 Apr; 25(4):463-8. PubMed ID: 19671887
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic spectrum of Charcot-Marie-Tooth disease due to LITAF/SIMPLE mutations: a study of 18 patients.
Guimarães-Costa R; Iancu Ferfoglia R; Leonard-Louis S; Ziegler F; Magy L; Fournier E; Dubourg O; Bouche P; Maisonobe T; Lacour A; Moerman A; Latour P; Stojkovic T
Eur J Neurol; 2017 Mar; 24(3):530-538. PubMed ID: 28211240
[TBL] [Abstract][Full Text] [Related]
36. Clinical predominance of proximal upper limb weakness in CMT1A syndrome.
Auer-Grumbach M; Wagner K; Strasser-Fuchs S; Löscher WN; Fazekas F; Millner M; Hartung HP
Muscle Nerve; 2000 Aug; 23(8):1243-9. PubMed ID: 10918262
[TBL] [Abstract][Full Text] [Related]
37. Genetic epidemiology of Charcot-Marie-Tooth disease.
Braathen GJ
Acta Neurol Scand Suppl; 2012; (193):iv-22. PubMed ID: 23106488
[TBL] [Abstract][Full Text] [Related]
38. Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain).
Lousa M; Vázquez-Huarte-Mendicoa C; Gutiérrez AJ; Saavedra P; Navarro B; Tugores A
J Peripher Nerv Syst; 2019 Mar; 24(1):131-138. PubMed ID: 30569560
[TBL] [Abstract][Full Text] [Related]
39. Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer.
Pantera H; Moran JJ; Hung HA; Pak E; Dutra A; Svaren J
Hum Mol Genet; 2018 Aug; 27(16):2830-2839. PubMed ID: 29771329
[TBL] [Abstract][Full Text] [Related]
40. Charcot-Marie-Tooth disease type 1A: mutational mechanisms and candidate gene.
Patel PI
Curr Opin Genet Dev; 1993 Jun; 3(3):438-44. PubMed ID: 8353419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
